A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
about
Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.Immune Activation: Contribution to AIDS-Associated Non-Hodgkin LymphomaIncreased expression of ganglioside GM1 in peripheral CD4+ T cells correlates soluble form of CD30 in Systemic Lupus Erythematosus patientsAssessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma.Cancer biomarkers in HIV patientsCirculating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.Circulating mediators of inflammation and immune activation in AIDS-related non-hodgkin lymphoma.High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides.Effects of long-term use of antiretroviral therapy on the prevalence of oral Epstein-Barr virusCirculating cytokine levels, Epstein-Barr viremia, and risk of acquired immunodeficiency syndrome-related non-Hodgkin lymphoma.Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-sponsored Workshop.Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipientsEvaluation of serum levels of sCD30L ligand in patients with ovarian cancer in terms of selected clinico-pathological factorsSoluble levels of CD27 and CD30 are associated with risk of non-Hodgkin lymphoma in three Chinese prospective cohorts.Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma riskA prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma.Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.A review of the role of lymphoma markers and occupational and environmental exposures.Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses.Acute myeloid leukemia targets for bispecific antibodies.Low expression of dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin-related protein in non-Hodgkin lymphoma and significant correlations with lactic acid dehydrogenase and β2-microglobulin.CD30 in myeloid malignancies: hitting the bull's-eye with an available dart.Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.Association between low-grade inflammation and Breast cancer and B-cell Myeloma and Non-Hodgkin Lymphoma: findings from two prospective cohortsPre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
P2860
Q33687930-23874025-ADDF-4C66-AC01-DAE731EC7F52Q33887336-07637FBB-8940-45D8-8106-AC935AC6E983Q33960141-C0EEF51B-038F-433D-BC7A-AEAF31CBE074Q34474354-A64C6A73-7629-44B4-A512-69F724CB9672Q34661370-32368EFF-51D9-42B7-BABA-66EBEEACAEF9Q35034487-F0970EA7-E502-4CD6-967A-8C1EC97AE4BDQ35093835-E7F7D907-545A-4A25-8256-385A7F33FCC8Q35112864-FBBEDF05-5EE3-49CD-AEBE-C69E55323C6AQ35186832-F40CFC50-3F2A-4FAF-ACB2-37FD7135B072Q35754143-FFEEFA43-8CF2-4512-8A3F-AC0634D52E99Q35830555-3F24746C-0EFE-473B-A823-5154EA4D4ACFQ35873666-78318749-66F4-43AE-821C-308BDF7711C1Q36243608-7B58B5BB-14DD-4B3B-8AEA-171BC2427C83Q36403297-4BBADBF6-DC79-41D5-8DB4-0A6B61AC29D1Q36592302-58F71798-26AD-43A5-9D71-35531C49B45EQ36942675-AC7A8AAA-18FA-4A0E-B144-A767C85AB4CFQ36983335-24F8F196-06AB-4AC6-8E5A-293E0D8F9D29Q36988704-2A2A9694-D187-4D44-B933-D8AEBB719106Q37083956-BC9AB961-09EA-4843-A731-F5D904EAFABBQ37323664-006A6648-E241-4A9F-A2C1-6C71F7ED11D5Q37962701-2F7F4D13-992E-462C-A632-8100C3E17C4EQ38029093-C27CCB4B-0EBD-4C4A-A985-3EDAC01EA2A2Q38375380-8269F7DE-625A-46AD-B3B3-3D69A1DF8299Q38930379-704F9912-4450-444B-AFE5-C520F26A668CQ39117761-B4947BD4-4237-4AEE-AA0B-4C9E0F6B9C8FQ42283552-6C7D5DC4-DD98-4A7D-9687-3A8BBA944B39Q44973239-5601E969-38F9-443F-9A32-AAB4337E83F7Q52718642-836215E3-E6DA-4D4E-BB86-2583CC5E2A6BQ57419693-DBA560C8-9B26-4122-B246-549C57E12E79Q58793783-7DF043AB-332E-4699-BB9D-4270CE0BF6BC
P2860
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
@en
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
@nl
type
label
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
@en
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
@nl
prefLabel
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
@en
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
@nl
P2093
P2860
P1433
P1476
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
@en
P2093
Betty Conde
Dalsu Baris
Martin M Oken
Otoniel Martinez-Maza
Wen-Yi Huang
William Hocking
P2860
P304
P356
10.1182/BLOOD-2009-04-217521
P407
P577
2009-07-28T00:00:00Z